Dr. Mark Allan Hartman, M.D. Radiology - Radiation Oncology Medicare: Accepting Medicare Assignments Practice Location: 3911 Avenue B, Suite G-100, Scottsbluff, NE 69361 Phone: 308-630-1348 Fax: 308-630-1445 |
Malonnie L Kinnison, MD Radiology - Diagnostic Radiology Medicare: Not Enrolled in Medicare Practice Location: 4021 Avenue B, Scottsbluff, NE 69361 Phone: 303-761-9190 Fax: 303-761-6278 |
Dr. Patricia J. Eastman, M.D. Radiology - Nuclear Radiology Medicare: Not Enrolled in Medicare Practice Location: 2 W 42nd St, Suite 2100, Scottsbluff, NE 69361 Phone: 308-630-2906 Fax: 308-632-6181 |
Gitesh Dhiraj Chheda, M.D. Radiology - Diagnostic Radiology Medicare: Accepting Medicare Assignments Practice Location: 4021 Avenue B, Scottsbluff, NE 69361 Phone: 303-761-9190 Fax: 720-874-4462 |
News Archive
BG Medicine, Inc., a privately-held developer of biomarker-based in vitro diagnostics, today announced the commercial launch in the European Union of a new, CE-marked test for the measurement of galectin-3 in human plasma or serum. Galectin-3 was first shown by researchers at the University of Maastricht, The Netherlands, to play an integral role in the development and progression of heart failure.
Tris Pharma, a specialty pharmaceutical company focused on developing innovative drug delivery technologies, today announced that the U.S. Food and Drug Administration has approved its New Drug Application for Karbinal ER (carbinoxamine maleate) Extended-release Oral Suspension 4mg/5ml, the first sustained-release histamine receptor blocking agent indicated for the treatment of seasonal and perennial allergic rhinitis in children ages 2 and up.
Starting June 2013, the Porter Cancer Care Center at Porter Adventist Hospital becomes one of the few facilities in the country to offer highly advanced radiation therapy and radiosurgery cancer treatment options using the new Varian TrueBeam image-guided radiotherapy system.
Nutra Pharma Corp. (OTCBB: NPHC), a biotechnology company that is developing treatments for Adrenomyeloneuropathy (AMN), HIV and Multiple Sclerosis (MS), has announced today its intent to launch a prescription analgesic, Nyloxin Rx, for the treatment of severe (Stage 3) chronic pain.
› Verified 1 days ago